Document is current
Any future updates will be listed below
-
Authors
Erhart, Friedrich http://orcid.org/0000-0002-9708-3126
Buchroithner, Johanna
Reitermaier, René
Fischhuber, Katrin
Klingenbrunner, Simone
Sloma, Ido
Hibsh, Dror
Kozol, Renana
Efroni, Sol
Ricken, Gerda
Wöhrer, Adelheid
Haberler, Christine
Hainfellner, Johannes
Krumpl, Günther
Felzmann, Thomas
Dohnal, Alexander M.
Marosi, Christine
Visus, Carmen
-
Funding
Funding for this research was provided by:
Austrian Research Promotion Agency (“Probio 1+2”, 837897, 848202)
European Program IAPP-24 (“Modicell”, 285875)
- License Information
-
More Information
Article History
Received: 26 August 2018
Accepted: 16 October 2018
First Online: 5 December 2018
Ethics approval and consent to participate
: The present work analyses the clinical trial “GBM-Vax” (NCT01213407/EudraCT2009-015979-27) immunologically. The study was approved by the Upper-Austrian ethical review committee (TRX2/P-II-018). All patients gave written informed consent also to concomitant immunological research.
: FE and AD were formerly employees of Activartis GmbH. GK, TF and CV held management positions at Activartis GmbH.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
